Login to Your Account

Pharma: Clinic Roundup

Tuesday, July 10, 2012
• Bayer HealthCare Pharmaceuticals Inc., a Wayne, N.J.-based subsidiary of Bayer AG, began enrolling patients in an international Phase II/III trial to evaluate BAY94-9027 as a prophylactic and on-demand treatment of hemophilia A.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription